Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
1,170
Views
0
CrossRef citations to date
0
Altmetric
Neurology

In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113

Michael Serbina Neurocrine Biosciences Inc., San Diego, CA, USAORCID Iconhttps://orcid.org/0000-0001-6876-7150
ORCID Icon,
Charles Yonana Neurocrine Biosciences Inc., San Diego, CA, USAORCID Iconhttps://orcid.org/0000-0002-6374-327X
ORCID Icon &
Michael L. Ganzb Real-world Evidence, Evidera, Waltham, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9702-2999
ORCID Icon
Pages 891-892 | Received 11 Jun 2021, Accepted 23 Jun 2021, Published online: 19 Jul 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.